IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL

被引：0
|
作者：
Doerner, T. [1 ]
Bowman, S. J. [2 ]
Fox, R. [3 ]
Mariette, X. [4 ]
Papas, A. [5 ]
Grader-Beck, T. [6 ]
Fisher, B. A. [2 ]
Barcelos, F. [7 ]
De Vita, S. [8 ]
Schulze-Koops, H. [9 ]
Moots, R. J. [10 ]
Junge, G. [11 ]
Woznicki, J. [12 ]
Sopala, M. [11 ]
Luo, W. [12 ]
Hueber, W. [11 ]
机构：
[1] Charite, Dept Med Rheumatol & Clin Immunol, Berlin, Germany
[2] Univ Hosp Birmingham NHS Fdn Trust, Dept Rheumatol, Birmingham, England
[3] Scripps Mem Hosp & Res Inst, La Jolla, CA USA
[4] Univ Paris Saclay, Paris, France
[5] Tufts Sch Dent Med, Div Oral Med, Boston, MA USA
[6] Johns Hopkins Sch Med, Div Rheumatol, Baltimore, MD USA
[7] Inst Portugues Reumatol, Lisbon, Portugal
[8] Univ Hosp Udine, Div Rheumatol, DAME, Udine, Italy
[9] Ludwig Maximilians Univ Munchen, Div Rheumatol & Clin Immunol, Munich, Germany
[10] Aintree Univ Hosp NHS Fdn Trust, Acad Rheumatol Dept, Liverpool, England
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2022年 / 40卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
119
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [1] Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren's Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging Trial
    Doerner, Thomas
    Bowman, Simon J.
    Fox, Robert
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Ben A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Luo, Wen-Lin
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2063 - 2065
  • [2] IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN'S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL
    Dorner, T.
    Bowman, S. J.
    Fox, R.
    Mariette, X.
    Papas, A.
    Grader-Beck, T.
    Fisher, B. A.
    Barcelos, F.
    De Vita, S.
    Schulze-Koops, H.
    Moots, R. J.
    Junge, G.
    Woznicki, J.
    Sopala, M.
    Luo, W. L.
    Hueber, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 593 - 594
  • [3] Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjogren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
    Bowman, Simon J.
    Fox, Robert
    Doerner, Thomas
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Benjamin A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert J.
    Junge, Guido
    Woznicki, Janice N.
    Sopala, Monika A.
    Luo, Wen-Lin
    Hueber, Wolfgang
    [J]. LANCET, 2022, 399 (10320): : 161 - 171
  • [4] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
    Fisher, Benjamin A.
    Mariette, Xavier
    Papas, Athena S.
    Grader-Beck, Thomas
    Bootsma, Hendrika
    Ng, Wan-Fai
    Van Daele, Paul
    Finzel, Stephanie
    Elgueta, Sergio
    Hermann, Josef
    McCoy, Sara
    Bookman, Arthur
    Sopala, Monika
    Luo, Wen-Lin
    Scheurer, Cornelia
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
  • [5] Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
    Muir, A.
    Goodman, Z.
    Levy, C.
    Janssen, H.
    Montano-Loza, A.
    Bowlus, C.
    Ding, D.
    Jia, C.
    McColgan, B.
    Myers, R.
    Subramanian, M.
    McHutchison, J.
    Manns, M.
    Chapman, R.
    Afdhal, N.
    Eksteen, B.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S73 - S73
  • [6] Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
    Pandya, Amit G.
    Ezzedine, Khaled
    Passeron, Thierry
    van Geel, Nanja
    Brown, Kurt
    Santos, Leandro
    Erskine, Lois
    Wagya, Kofi
    Blauvelt, Andrew
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [7] Linzagolix for treating endometriosis-associated pain: efficacy and safety results from a randomized, placebo-controlled, multinational, phase 2b dose-ranging trial
    Bestel, E.
    Humberstone, A.
    Lecomte, V.
    Dubouloz, R.
    Terrill, P.
    Donnez, J.
    Taylor, H.
    Taylor, R.
    Loumaye, E.
    [J]. HUMAN REPRODUCTION, 2019, 34 : 64 - 64
  • [8] Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
    Oakes, Tina Marie Myers
    Skljarevski, Vladimir
    Zhang, Qi
    Kielbasa, William
    Hodsdon, Michael E.
    Detke, Holland C.
    Camporeale, Angelo
    Saper, Joel R.
    [J]. CEPHALALGIA, 2018, 38 (06) : 1015 - 1025
  • [9] Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial
    Dubourg, Julie
    Ueki, Kohjiro
    Grouin, Jean-Marie
    Fouqueray, Pascale
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 800 - 810
  • [10] Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjogren's Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
    Bowman, Simon
    Fox, Robert
    Doerner, Thomas
    Mariette, Xavier
    Papas, Athena
    Grader-Beck, Thomas
    Fisher, Benjamin A.
    Barcelos, Filipe
    De Vita, Salvatore
    Schulze-Koops, Hendrik
    Moots, Robert J.
    Junge, Guido
    Woznicki, Janice
    Sopala, Monika
    Luo, Wen-Lin
    Hueber, Wolfgang
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345